Pyroptosis, a form of inflammatory cell death, has gained increasing attention due to its role in innate immunity and disease. The discovery of the gasdermin family has expanded the research scope of pyroptosis. This review provides an overview of pyroptosis, its relationship with tumors, and its significance in tumor treatment. Pyroptosis is characterized by the release of inflammatory molecules and cell membrane rupture, distinct from apoptosis. The gasdermin superfamily, including GSDMA, GSDMB, GSDMC, and GSDMD, plays a crucial role in pyroptosis by forming pores in the cell membrane. Caspases and granzymes can activate gasdermins, leading to pyroptosis. Pyroptosis is involved in various tumors, including melanoma, breast cancer, colorectal cancer, gastric cancer, and hepatocellular carcinoma. In melanoma, GSDME deficiency leads to larger tumors, suggesting a tumor-inhibitory effect. In breast cancer, high levels of GSDMC are associated with poor survival, and antibiotics can promote GSDMC expression, leading to pyroptotic death. In colorectal cancer, GSDMC downregulation is linked to tumor progression, while GSDME is a potential diagnostic marker. In gastric cancer, GSDMB overexpression is associated with invasion, and GSDMD downregulation may benefit treatment. In hepatocellular carcinoma, DNFA5 overexpression inhibits cell proliferation, and berberine induces pyroptosis. Pyroptosis is a double-edged sword, and its rational use can help understand tumor formation and development, providing new insights for drug development.Pyroptosis, a form of inflammatory cell death, has gained increasing attention due to its role in innate immunity and disease. The discovery of the gasdermin family has expanded the research scope of pyroptosis. This review provides an overview of pyroptosis, its relationship with tumors, and its significance in tumor treatment. Pyroptosis is characterized by the release of inflammatory molecules and cell membrane rupture, distinct from apoptosis. The gasdermin superfamily, including GSDMA, GSDMB, GSDMC, and GSDMD, plays a crucial role in pyroptosis by forming pores in the cell membrane. Caspases and granzymes can activate gasdermins, leading to pyroptosis. Pyroptosis is involved in various tumors, including melanoma, breast cancer, colorectal cancer, gastric cancer, and hepatocellular carcinoma. In melanoma, GSDME deficiency leads to larger tumors, suggesting a tumor-inhibitory effect. In breast cancer, high levels of GSDMC are associated with poor survival, and antibiotics can promote GSDMC expression, leading to pyroptotic death. In colorectal cancer, GSDMC downregulation is linked to tumor progression, while GSDME is a potential diagnostic marker. In gastric cancer, GSDMB overexpression is associated with invasion, and GSDMD downregulation may benefit treatment. In hepatocellular carcinoma, DNFA5 overexpression inhibits cell proliferation, and berberine induces pyroptosis. Pyroptosis is a double-edged sword, and its rational use can help understand tumor formation and development, providing new insights for drug development.